Skip to main content
    R

    Regenxbio Inc (RGNX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.32
    -0.32 (-4.19%)

    Market Cap: $505.18M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Regenxbio Inc (RGNX) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Regenxbio (RGNX) is expected to report earnings on Mar 3, 2027. In the quarter ended Sep 30, 2026, Regenxbio reported EPS of -$0.62, above the -$1.35 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    45%(18/40)
    Avg Surprise
    +1.36%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 3, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$1.01
    Range-$1.86 - $1.21
    13 analysts
    Revenue Consensus
    $28.87M
    Range$6.17M - $169.05M
    11 analysts
    Reports May 12, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.99
    Range-$0.99 - -$0.99
    1 analysts
    EPS Revisions
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.32-206.2%
    60d ago-$1.23+19.7%
    30d ago-$1.23+19.7%
    7d ago-$1.23+19.7%
    Current-$0.99
    Revenue Consensus
    $9.00M
    Range$7.00M - $10.00M
    3 analysts

    Next Report

    RGNX has an expected report date of Mar 3, 2027.

    RGNX Earnings Call

    The latest RGNX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, RGNX beat 18, missed 21 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $9.16M, down 69.2% from $29.73M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.62-$1.35-$1.63 - -$0.89+54.07%BeatN/A94 up, 2 downNov 5, 2026$9.16M
    Jun 30, 2026$0.43$0.12-$1.23 - $0.73+258.33%BeatN/A70 up, 1 downAug 6, 2026$108.02M
    Mar 31, 2026-$1.72-$1.41-$1.58 - -$1.23-21.99%Miss-1533.3%50 up, 4 downMay 14, 2026$6.39M
    Dec 31, 2025-$1.30-$0.72-$1.65 - $0.43-80.71%MissN/A80 up, 2 downMar 5, 2026$30.34M
    Sep 30, 2025-$1.20-$1.30-$1.68 - -$0.89+7.69%BeatN/A60 up, 1 downNov 6, 2025$29.73M
    Jun 30, 2025-$1.38-$1.13-$1.34 - -$0.75-22.12%MissN/A62 up, 2 downAug 7, 2025$21.36M
    Mar 31, 2025$0.12$0.49-$1.21 - $1.07-75.51%MissN/A51 up, 0 downMay 12, 2025$89.01M
    Dec 31, 2024-$1.01-$1.08-$1.33 - -$0.46+6.86%BeatN/A71 up, 0 downMar 13, 2025$21.21M
    Sep 30, 2024-$1.17-$1.10-$1.28 - -$1.05-6.36%MissN/A90 up, 0 downNov 6, 2024$24.20M
    Jun 30, 2024-$1.05-$1.31-$1.41 - -$1.11+19.85%BeatN/A80 up, 0 downAug 1, 2024$22.30M
    Mar 31, 2024-$1.34-$1.26-$1.50 - -$1.11-6.35%MissN/A100 up, 0 downMay 8, 2024$15.62M
    Dec 31, 2023-$1.43-$1.27-$1.52 - -$0.77-12.60%MissN/A90 up, 0 downFeb 27, 2024$22.21M
    Sep 30, 2023-$1.41-$1.52-$1.74 - -$1.26+7.24%BeatN/A80 up, 0 downNov 8, 2023$28.91M
    Jun 30, 2023-$1.66-$1.21-$1.55 - -$1.20-37.19%MissN/A60 up, 0 downAug 2, 2023$19.98M
    Mar 31, 2023-$1.53-$1.41-$1.77 - -$1.28-8.51%MissN/A60 up, 0 downMay 3, 2023$19.14M
    Dec 31, 2022-$1.38-$1.23-$1.67 - -$0.22-12.20%Miss-120.7%70 up, 0 downFeb 28, 2023$31.34M
    Sep 30, 2022-$1.75-$1.46-$1.56 - -$1.37-19.86%MissN/A70 up, 0 downNov 3, 2022$26.51M
    Jun 30, 2022-$1.58-$1.54-$1.64 - -$1.36-2.60%MissN/A70 up, 1 downAug 3, 2022$32.65M
    Mar 31, 2022-$1.79-$1.28-$1.39 - -$1.23-39.84%MissN/A50 up, 0 downMay 4, 2022$22.22M
    Dec 31, 2021$6.67$4.71-$1.31 - $9.39+41.61%BeatN/A6N/AMar 1, 2022$379.77M
    Sep 30, 2021-$1.37-$1.12-$1.55 - $0.00-22.32%Miss-426.2%6N/ANov 2, 2021$30.77M
    Jun 30, 2021-$1.36-$1.15-$1.70 - -$0.93-18.26%MissN/A7N/AAug 9, 2021$22.04M
    Mar 31, 2021-$1.20-$1.30-$1.63 - -$0.90+7.69%BeatN/A7N/AMay 5, 2021$37.77M
    Dec 31, 2020-$1.24-$0.43-$1.70 - $4.10-188.37%MissN/A7N/AMar 1, 2021$21.45M
    Sep 30, 2020$0.42-$1.01-$1.36 - -$0.70+141.58%BeatN/A6N/ANov 4, 2020$98.91M
    Jun 30, 2020-$0.91-$0.93-$1.07 - -$0.85+2.15%BeatN/A4N/AAug 6, 2020$16.57M
    Mar 31, 2020-$1.08-$0.87-$1.02 - -$0.60-24.14%MissN/A3N/AMay 7, 2020$17.64M
    Dec 31, 2019-$0.72-$0.95-$1.19 - $0.25+24.21%Beat-754.5%5N/AFeb 26, 2020$11.77M
    Sep 30, 2019-$0.94-$0.24-$1.09 - -$0.24-291.67%MissN/A5N/ANov 5, 2019$14.70M
    Jun 30, 2019-$0.83-$0.77-$0.85 - $0.09-7.79%Miss-376.7%5N/AAug 7, 2019$7.88M
    Mar 31, 2019-$0.89-$0.89-$0.98 - -$0.770.00%In line-129.3%4N/AMay 7, 2019$884000
    Dec 31, 2018$0.11-$0.34-$0.38 - -$0.31+132.35%BeatN/A4N/AFeb 27, 2019$40.78M
    Sep 30, 2018-$0.56-$0.81-$0.86 - $0.31+30.86%BeatN/A3N/ANov 7, 2018$5.31M
    Jun 30, 2018$0.30$0.56$0.56 - $1.90-46.43%MissN/A2N/AAug 8, 2018$40.03M
    Mar 31, 2018$3.04$1.07-$0.88 - $1.63+184.11%BeatN/A5N/AMay 8, 2018$132.39M
    Dec 31, 2017-$0.51-$0.82-$0.92 - -$0.67+37.80%BeatN/A5N/AMar 6, 2018$8.60M
    Sep 30, 2017-$0.67-$0.73-$0.80 - -$0.66+8.22%BeatN/A4N/ANov 8, 2017$1.34M
    Jun 30, 2017-$0.47-$0.80-$0.81 - -$0.69+41.25%BeatN/A2N/AAug 8, 2017N/A
    Mar 31, 2017-$0.82-$0.76N/A-7.89%MissN/AN/AN/AMay 9, 2017$455000
    Dec 31, 2016-$0.74-$0.75N/A+1.33%BeatN/AN/AN/AMar 7, 2017$1.70M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.76, after -$4.57 the year before. It was -$2.39 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.76N/A
    Dec 31, 2024-$4.57N/A
    Dec 31, 2023-$6.03N/A
    Dec 31, 2022-$6.50-337.2%
    Dec 31, 2021$2.74N/A
    Dec 31, 2020-$2.81N/A
    Dec 31, 2019-$3.38-217.0%
    Dec 31, 2018$2.89N/A
    Dec 31, 2017-$2.47N/A
    Dec 31, 2016-$2.39N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,300 words across 14 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,31114
    2026Q1Mar 31, 20266,90716
    2025Q4Dec 31, 20259,43316
    2025Q3Sep 30, 20256,45018
    2025Q1Mar 31, 20256,51016
    2024Q4Dec 31, 20247,15716
    2024Q3Sep 30, 20246,99613
    2024Q2Jun 30, 20245,65113

    2026Q3 Earnings Call

    Opening remarks

    Patrick Christmas Chief Legal Officer Good morning, and thank you for joining us today. Earlier this morning, REGENXBIO released financial and operating results for the third quarter ended September 30, 2026. The press release is available on our website at www.regenxbio.com. Today's conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend and other words of similar meaning. Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are described in the Risk Factors and the Management's Discussion and Analysis section of REGENXBIO's annual report on Form 10-K for the full year ended December 31, 2025, and comparable Risk Factors sections of REGENXBIO's quarterly report on Form 10-Q, which will be on file with the Securities and Exchange Commission and available on the SEC's website. Any information we provide on this conference call is provided only as of the date of this call, November 5, 2026, and we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events or otherwise. Please be advised that today's call is being recorded and webcast. In addition, any unaudited or pro forma financial information that may be provided is preliminary and does not purport to project financial positions or operating results of the company. Actual results may differ materially. I'll now turn the call to Curran Simpson, President and CEO of REGENXBIO. Curran?

    Curran Simpson President and CEO Thank you, Patrick, and good morning, everyone. Thank you for joining us today. This is an exciting time for REGENXBIO. We are on the cusp of multiple potential regulatory approvals and are preparing for commercialization. Joining me today are Dr. Steve Pakola, our Chief Medical Officer; and Mitch Chan, our Chief Financial Officer. I'll provide an update on our lead programs before turning it over to them for additional details. I'll begin with sura-vec, our potential first-in-class gene therapy for wet AMD and diabetic retinopathy developed in collaboration with AbbVie. Ahead of our top line pivotal readout expected later this year, last month, we hosted an investor event featuring five leading retina specialists. They discussed the opportunity for sura-vec to transform the wet AMD treatment paradigm. I want to highlight three key takeaways from the event. First, the unmet need in wet AMD remains significant. While anti-VEGF therapies are highly effective, the burden of frequent injections can be difficult for patients to sustain over time.

    Frequently Asked Questions About RGNX

    When is Regenxbio's next earnings date?

    Regenxbio's next earnings report is expected for Mar 3, 2027.

    Did RGNX beat earnings estimates last quarter?

    Yes. Regenxbio reported EPS of -$0.62 for the quarter ended Sep 30, 2026, above the -$1.35 estimate, a 54.07% surprise.

    What EPS do analysts expect from RGNX next quarter?

    The consensus EPS estimate for Regenxbio for the quarter ending Dec 31, 2026 is -$1.01 from 13 analysts, with estimates from -$1.86 to $1.21.

    How often does RGNX beat earnings estimates?

    Regenxbio beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +15.83%.